|
UPDATE 1-AstraZeneca builds pipeline with $232 mln Synairgen asthma deal
Reuters LONDON, June 12 (Reuters) – AstraZeneca has struck a deal worth up to $232 million in milestone payments to acquire rights to a drug from Synairgen for treating respiratory tract viral infections in patients with severe asthma. Britain's second-biggest … |
View full post on asthma – Google News